logo

Progenics Pharmaceuticals Inc (PGNX)



Trade PGNX now with
  Date
  Headline
8/9/2017 7:35:22 AM Progenics Pharma Q2 Revenue $2.8 Mln, Down From $8.5 Mln Last Year
5/4/2017 8:14:21 AM Progenics Pharma Q1 Net Loss Attributable To Progenics $16.4 Mln Or $0.23/Shr Vs Loss $12.7 Mln Or $0.18/Shr Last Year
3/30/2017 6:04:40 AM Progenics: Phase 2b Trial Of Radiotherapeutic Candidate, AZEDRA (iobenguane I 131) Injection, Achieved Primary Endpoint
3/9/2017 7:38:59 AM Progenics Pharmaceuticals Q4 Net Loss Attributable $7.2 Mln Or $0.10 Per Share
2/15/2017 7:44:55 PM Progenics Pharma And Shutterfly To Join S&P SmallCap 600
2/14/2017 7:12:15 AM Progenics Begins Phase 1 Clinical Trial Of PSMA-Targeted Therapeutic Candidate 1095 For Metastatic Prostate Cancer
12/7/2016 8:33:39 AM Progenics Says First Patient Dosed In Phase 2/3 Clinical Trial Of PSMA-Targeted PET/CT Imaging Agent PyL
8/4/2016 7:43:34 AM Progenics Q2 Loss Per Share $0.08 Vs Loss $0.17 Last Year
7/26/2016 8:38:54 AM Progenics Receives $50 Mln Milestone Payment From Worldwide Collaboration Partner, Valeant
7/19/2016 6:16:31 PM Progenics Pharmaceuticals, Trading Expected To Resume At 6:25 PM ET
7/19/2016 6:06:43 PM Progenics Pharmaceuticals, Trading Halted; Pending News.